Director of the Office of the National Ozone Layer Protection Plan announced the elimination of destructive gases in the Iranian industry by 2030.
Ebrahim Hajizadeh said in the first workshop to inform Iran about the achievements of replacing and producing non-fissure respiratory spray, which was held today in a pharmaceutical company, said: “Currently, 9,500 tons of destructive gas is from 1,358 units of our country’s manufacturing industries to 2010 has been eliminated, and by the year 2030 we have to eliminate all the destructive gases in our country’s industries and pharmaceuticals.
“According to our international commitments, we need to remove about 10 percent of the 5,000 tons of destructive gas in our industry by 2015, and in the coming years, including in 2020, we will reduce the elimination of destructive gas by 70 percent,” he said. Eventually, in the year 2030 there should be no ozone depleting gas in the country.
Hajizadeh said that there are no facilities for producing ozone-depleting substances in the country, adding that Iran is a consumer of ozone-depleting substances that imports into the country through imports.
He said: “One of our projects in the field of eliminating destructive gas is the project of respiratory spray, which about 7 million patients in our country also need it because of asthma, and we are also obliged, according to international obligations, to have destructive gases in sprays Removing the respiratory tract (CFC) and preventing new materials that do not pose a risk to the ozone layer.
Hajizadeh, referring to Iran’s cooperation with international agencies for the removal of ozone-depleting gases, added: “The Food, Drug, Food and Drug Administration, the Ministry of Commerce and a pharmaceutical company are currently working on replacing new gases instead of old gas (CFCs).” .
Following on from the first workshop on informing and reviewing Iran’s achievements in the replacement and production of non-frontal respiratory spray, Anaraki, a consultant to the Food and Drug Organization, also stated that Iran joined the Montreal Protocol to remove malware in 1989, adding: “We were able to breathe in 2010, We produce native products by removing destructive gases (CFCs).
Referring to the collaboration of the Food and Drug Administration and the United Nations Environment Program and the United Nations Development Organization (UNDP), the Food and Drug Administration (FDA) is the official authority responsible for monitoring the quality of the safety and efficacy of medicines in the country.
Anaraki, referring to the drug evaluation steps before and after the registration, added: Clinical studies of the GMP of the pharmaceutical factories, the post-registration evaluation and safety and efficacy of the drug, and finally the review of the conditions for the distribution of the drug by the Food and Drug Administration are made.
He continued: To eliminate destructive gases (CFCs) in pharmaceutical plants, having technical provisions, raw materials, packaging requirements, laboratory equipment and product line machinings is vital.
He also referred to the main programs of the Food and Drug Administration for the elimination of gaseous fumes (CFCs), saying that the registration of fast-free medicines (CFCs), the import ban on products (CFCs) from March 86 and the registration of drugs with new gases HSA has also been carried out along with the holding of workshops.
“We did not import any CFCs from the country since 2011, and this year, medications produced by HSA have entered the pharmaceutical market,” said Anaraki.
In the follow up to this workshop on the development of non-frontal breath sprays, Malayeri, a former member of our country at the United Nations Industrial Development Organization (UNDP), also described the development of non-fatal respiratory sprays, discussing issues of attracting international funds through Iran. .
At the end of the workshop, Iran’s achievements in the field of replacing and producing non-frontal breath sprays of reporters were also visited by the technical and manufacturing parts of the pharmaceutical company.